• 1
    American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia. Arlington, VA: American Psychiatric Association, 2004.
  • 2
    Thieda P, Beard S, Richter A, Kane J. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 2003;54: 50816.
  • 3
    Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff 2004;23: 13546.
  • 4
    Essock SM, Frisman LK, Covell NH, Hargreaves WA. Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals. Arch Gen Psychiatry 2000;57: 98794.
  • 5
    Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997; 337: 80915.
  • 6
    Hudson TJ, Sullivan G, Feng W, et al. Economic evaluations of novel antipsychotic medications: a literature review. Schizophr Res 2003;60: 199218.
  • 7
    Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003;290: 2693702.
  • 8
    Liu GG, Sun SX, Christensen DB, Luo X. Cost comparisons of olanzapine and risperidone in treating schizophrenia. Ann Pharmacother 2004;38: 13441.
  • 9
    Edgell ET, Andersen SW, Johnstone BM, et al. Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia. Pharmacoeconomics 2000;18: 56779.
  • 10
    Rascati KL, Johnsrud MT, Crismon ML, et al. Olanzapine versus risperidone in the treatment of schizophrenia: a comparison of costs among Texas Medicaid recipients. Pharmacoeconomics 2003;21: 68397.
  • 11
    Gibson PJ, Damler R, Jackson EA, et al. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a Medicaid population. Value Health 2004;7: 2235.
  • 12
    Mauskopf JA, David K, Grainger DL, Gibson PJ. Annual health outcomes and treatment costs for schizophrenia populations. J Clin Psychiatry 1999;60: 1422.
  • 13
    Tunis SL, Johnstone BM, Loosbrock DL, et al. Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. J Clin Psychiatry 1999;60: 3845.
  • 14
    Rosenheck R, Doyle J, Leslie D, Fontana A. Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs. Schizophr Bull 2003;29: 8193.
  • 15
    Glick ID, Berg PH. Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. Int Clin Psychopharmacol 2002;17: 658.
  • 16
    Menzin J, Boulanger L, Friedman M, et al. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv 2003;54: 71923.
  • 17
    Hugenholtz GW, Heerdink ER, Nolen WA, Egberts AC. Less medication switching after initial start with atypical antipsychotics. Eur Neuropsychopharmacol 2004;14: 15.
  • 18
    Freedman R. Schizophrenia. N Engl J Med 2003;349: 173849.
  • 19
    Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutic trials. J Chronic Dis 1967; 20: 63748.
  • 20
    Tunis SR, Stryer DB, Clancy CM. Practical Clinical Trials. Increasing the value of clinical research for decision making in clinical and health policy. Special communication. JAMA 2003;290: 162432.
  • 21
    Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003;29: 1531.
  • 22
    First M, Spitzer R, Gibbon M, Williams J. Structured Clinical Interview for DSM-IV Axis I Disorders-Administration Booklet. Washington: American Psychiatric Press, 1994.
  • 23
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th ed.). Washington: American Psychiatric Association, 1994.
  • 24
    Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10: 799812.
  • 25
    Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13: 26176.
  • 26
    Tunis SL, Johnstone BM, Kinon BJ, et al. Designing naturalistic prospective studies of economic and effectiveness outcomes associated with novel antipsychotic therapies. Value Health 2000;3: 23242.
  • 27
    Lehman AF. A quality of life interview for the chronically mentally ill. Eval Program Plann 1988; 11: 62.
  • 28
    Lehman AF. Evaluating outcomes of treatments for persons with psychotic disorders. J Clin Psychiatry 1996;57: 617.
  • 29
    Cook PE, Goldberg JO, Van Lieshout RJ. Benefits of switching from typical to atypical antipsychotic medications: a longitudinal study in a community-based setting. Can J Psychiatry 2002;47: 8704.
  • 30
    Cramer JA, Rosenheck R, Xu W. Quality of life in schizophrenia: a comparison of instruments. Schizophr Bull 2000;26: 65966.
  • 31
    US Food and Drug Administration. COSTART. Rockville, MD: US FDA, 1990.
  • 32
    Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970; 212(Suppl.):S1119.
    Direct Link:
  • 33
    Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154: 6726.
  • 34
    Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine vs. risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17: 40718.
  • 35
    Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158: 76574.
  • 36
    American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27: 596601.
  • 37
    Revicki DA, Paramore LC, Sommerville KW, et al. Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. J Clin Psychiatry 2003;64: 28894.
  • 38
    Hart A, Hopkins C, Ford B, eds. International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM). Salt Lake City, UT: Medicode, 2001.
  • 39
    Centers for Medicare and Medicaid Services (CMS). Available from:[Accessed December 17, 2004.].
  • 40
    Dixon L, Lyles A, Smith C, et al. Use and costs of ambulatory care services among Medicare enrollees with schizophrenia. Psychiatr Serv 2001;52: 78692.
  • 41
    Gianfrancesco F, Durkin MB, Mahmoud R, Wang RH. Use of healthcare services by patients treated with risperidone versus conventional antipsychotic agents. Pharmacoeconomics 2002;20: 41327.
  • 42
    Medical Economics Staff. Drug Topics Red Book: Pharmacy's fundamental reference. Montvale, NJ: Medical Economic Data Production Company, Inc., 2001.
  • 43
    Academy of Managed Care Pharmacy. A Guide to Understanding Common Prescription Drug Pricing Terms. Alexandria, VA: Academy of Managed Care Pharmacy, 2002.
  • 44
    Medicaid Drug Rebate Program. Available from:[Accessed December 13, 2004.].
  • 45
    SAS Institute. SAS/STAT User's Guide. Cary, NC: SAS Institute, 1999.
  • 46
    Polsky D, Glick HA, Wilke R, Schulman K. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. Health Econ 1997;6: 24352.
  • 47
    Obenchain RL. Resampling and multiplicity in cost-effectiveness inference. J Biopharm Stat 1999;9: 56382.
  • 48
    Obenchain RL, Johnstone BM. Mixed model imputation of cost data for early discontinuers from a randomized clinical trial. Drug Inf J 1999;33: 191209.
  • 49
    Nyhuis A, Stensland M, Faries D. Calculating Responder Days for Cost-Effectiveness Studies. Colorado Springs, CO: International Congress on Schizophrenia Research, 2003.
  • 50
    Newgard CD, Hedges JR, Mullins AM. Advanced statistics: the propensity score – a method for estimating treatment effect in observational research. Acad Emerg Med 2004;11: 95361.
  • 51
    Diehr P, Yanez D, Ash A, et al. Methods for analyzing health care utilization and costs. Ann Rev Public Health 1999;20: 12544.
  • 52
    Good P. Permutation Tests: A Practical Guide to Resampling Methods for Testing Hypotheses. New York: Springer-Verlag, 2000.
  • 53
    Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000;11: 56170.
  • 54
    Faries D, Nyhuis A, Tunis SL, Hernan M. Assessing effectiveness in the presence of treatment switching: data from an effectiveness study of antipsychotics. Alexandria, VA: ISPOR Annual Meeting, 2004.
  • 55
    Mahmoud R, Engelhart L, Ollendorf D. The risperidone outcomes study of effectiveness (ROSE): a model for evaluating treatment strategies in typical psychiatric practice. J Clin Psychiatry 1999;60: 428.
  • 56
    Hedley AA, Ogden CL, Johnson CL, et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002. JAMA 2004; 291: 284750.
  • 57
    Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264: 251118.
  • 58
    Margolese HC, Malchy L, Negrete JC, et al. Drug and alcohol use among patients with schizophrenia and related psychosis: levels and consequences. Schizophr Res 2004;67: 15766.
  • 59
    Hargreaves WA, Gibson PJ. Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review. CNS Drugs 2005;19: 393410.
  • 60
    Dossenbach M, Erol A, El Mahfoud Kessaci M, et al. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry 2004;65: 31221.
  • 61
    Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60: 55364.
  • 62
    Davis JM, Chen N. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and International Trials. J Clin Psychiatry 2001;62: 75771.
  • 63
    Ritsner M, Modai I, Endicott J. Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients. J Clin Psychiatry 2000;61: 8809.
  • 64
    McCombs JS, Nichol MB, Stimmel GL. Use patterns for antipsychotic medications in Medicaid patients with schizophrenia. J Clin Psychiatry 1999;60: 511.
  • 65
    Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55: 88691.
  • 66
    Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizoph Bull 1995;21: 41929.
  • 67
    Soumerai S, McLaughlin T, Ross-Denan D, et al. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med 1994;331: 6505.
  • 68
    Tunis SL, Ascher-Svanum H, Stensland M, Kinon BJ. Assessing the value of antipsychotics for treating schizophrenia: the importance of evaluating and interpreting the clinical significance of individual service costs. Pharmacoeconomics 2004;22: 18.
  • 69
    Wolff N, Helminiak TW, Tebes JK. Getting the cost right in cost-effectiveness analyses. Am J Psychiatry 1997;154: 73643.
  • 70
    Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. Panel on cost-effectiveness in health and medicine. JAMA 1996;276: 11727.
  • 71
    Neumann PJ. Why don’t Americans use cost-effectiveness analysis? Am J Manag Care 2004;10: 30812.